A new treatment for cognitive impairment related to vascular dementia and Alzheimer's disease
PNA5: A Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Vascular Dementia and Alzheimer's Disease Related Dementia: an FDA required Toxicology Study
This study is testing a new treatment called PNA5 that could help improve thinking and memory for people at risk of dementia by reducing inflammation and boosting blood flow to the brain, making sure it's safe before moving on to the next steps.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-10910078 on NIH RePORTER |
What this research studies
This research focuses on developing a novel peptide called PNA5, which acts as an agonist for the Mas receptor, to treat cognitive impairment in individuals at risk for vascular dementia and Alzheimer's disease. The study aims to conduct FDA-required toxicology and safety assessments to ensure the peptide's effectiveness and safety before moving to clinical trials. By targeting inflammation and improving blood flow to the brain, PNA5 could potentially slow down or prevent cognitive decline in at-risk patients. The research is crucial as it addresses a significant unmet medical need in the growing population of individuals facing dementia.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with mild cognitive impairment who are at risk for vascular contributions to cognitive impairment and dementia.
Not a fit: Patients with advanced stages of dementia or those without cognitive impairment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option to prevent cognitive decline in patients at risk for vascular dementia and Alzheimer's disease.
How similar studies have performed: Previous studies have shown promising results with similar anti-inflammatory approaches in treating cognitive impairment, indicating potential for success in this novel application.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Hay, Meredith — University of Arizona
- Study coordinator: Hay, Meredith
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.